Ping Zhou1, Shiva Gautam, Abram Recht. 1. Joint Center for Radiation Therapy, Harvard Medical School, Boston, MA, USA. pzhou@partners.org
Abstract
BACKGROUND: Young women have worse outcome following breast-conserving therapy (BCT) than do older patients in many studies. We examined how clinical, pathological, and treatment factors affect these results. METHODS: Between 1993 and 1999, 130 patients age 40 years or younger with stage I or II breast cancer were treated with BCT. The median radiation dose to the tumor bed was 61 Gy; 80% of patients received chemotherapy; and 29% of 72 patients with estrogen-receptor positive tumors received tamoxifen. Median follow-up was 93 months. RESULTS: Fifteen patients (12%) developed an ipsilateral breast tumor recurrence (IBTR), with or without other simultaneous failure sites. The Kaplan-Meier 5- and 8-year actuarial rates were 8% and 14%, respectively. The 74 patients with grade 3 tumors had a higher IBTR rate (8-year actuarial rate, 18%) than the 54 patients with grade 1-2 lesions (7%) (P = 0.09). Six patients developed contralateral breast cancers, and 17 developed distant metastases (DM). The 8-year actuarial rates for freedom-from-DM, relapse-free survival, and overall survival were 85%, 72% and 96%, respectively. CONCLUSION: This represents one of the largest series of young women treated with BCT, using an approach similar to current practice. The IBTR rate was substantially lower than in many past studies, but still higher than would be expected for older women. This appeared largely due to the increased rate of IBTR in patients with grade 3 tumors. If this observation is confirmed, further analysis of this subgroup may lead to ways of reducing the risk of IBTR.
BACKGROUND: Young women have worse outcome following breast-conserving therapy (BCT) than do older patients in many studies. We examined how clinical, pathological, and treatment factors affect these results. METHODS: Between 1993 and 1999, 130 patients age 40 years or younger with stage I or II breast cancer were treated with BCT. The median radiation dose to the tumor bed was 61 Gy; 80% of patients received chemotherapy; and 29% of 72 patients with estrogen-receptor positive tumors received tamoxifen. Median follow-up was 93 months. RESULTS: Fifteen patients (12%) developed an ipsilateral breast tumor recurrence (IBTR), with or without other simultaneous failure sites. The Kaplan-Meier 5- and 8-year actuarial rates were 8% and 14%, respectively. The 74 patients with grade 3 tumors had a higher IBTR rate (8-year actuarial rate, 18%) than the 54 patients with grade 1-2 lesions (7%) (P = 0.09). Six patients developed contralateral breast cancers, and 17 developed distant metastases (DM). The 8-year actuarial rates for freedom-from-DM, relapse-free survival, and overall survival were 85%, 72% and 96%, respectively. CONCLUSION: This represents one of the largest series of young women treated with BCT, using an approach similar to current practice. The IBTR rate was substantially lower than in many past studies, but still higher than would be expected for older women. This appeared largely due to the increased rate of IBTR in patients with grade 3 tumors. If this observation is confirmed, further analysis of this subgroup may lead to ways of reducing the risk of IBTR.
Authors: D Ribnikar; J M Ribeiro; D Pinto; B Sousa; A C Pinto; E Gomes; E C Moser; M J Cardoso; F Cardoso Journal: Curr Treat Options Oncol Date: 2015-04
Authors: Philippa Youl; Shoni Philpot; Julie Moore; Michelle Morris; David E Theile Journal: Breast Cancer Res Treat Date: 2022-03-07 Impact factor: 4.872
Authors: Heather A Jones; Ninja Antonini; Augustinus A M Hart; Johannes L Peterse; Jean-Claude Horiot; Françoise Collin; Philip M Poortmans; S Bing Oei; Laurence Collette; Henk Struikmans; Walter F Van den Bogaert; Alain Fourquet; Jos J Jager; Dominic A X Schinagl; Carla C Wárlám-Rodenhuis; Harry Bartelink Journal: J Clin Oncol Date: 2009-08-31 Impact factor: 44.544
Authors: Irene Dankwa-Mullan; Judy George; M Christopher Roebuck; Joseph Tkacz; Van C Willis; Fredy Reyes; Yull E Arriaga Journal: Breast Cancer Res Treat Date: 2021-03-10 Impact factor: 4.872
Authors: Elrasheid H A Kheirelseid; Jennifer M E Boggs; Catherine Curran; Ronan W Glynn; Cara Dooley; Karl J Sweeney; Michael J Kerin Journal: BMC Cancer Date: 2011-08-28 Impact factor: 4.430